HK1201750A1 - 使用 激酶抑制劑的癌症治療 - Google Patents

使用 激酶抑制劑的癌症治療

Info

Publication number
HK1201750A1
HK1201750A1 HK15102376.3A HK15102376A HK1201750A1 HK 1201750 A1 HK1201750 A1 HK 1201750A1 HK 15102376 A HK15102376 A HK 15102376A HK 1201750 A1 HK1201750 A1 HK 1201750A1
Authority
HK
Hong Kong
Prior art keywords
tor
cancer
treatment
kinase inhibitors
tor kinase
Prior art date
Application number
HK15102376.3A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Lilly Loraine Wong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of HK1201750A1 publication Critical patent/HK1201750A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102376.3A 2012-03-15 2015-03-09 使用 激酶抑制劑的癌症治療 HK1201750A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1201750A1 true HK1201750A1 (zh) 2015-09-11

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102376.3A HK1201750A1 (zh) 2012-03-15 2015-03-09 使用 激酶抑制劑的癌症治療

Country Status (22)

Country Link
US (1) US20130245026A1 (zh)
EP (1) EP2825170B1 (zh)
JP (3) JP2015510891A (zh)
KR (3) KR20210071101A (zh)
CN (2) CN104519885A (zh)
AU (1) AU2013203153B2 (zh)
BR (1) BR112014022703A2 (zh)
CA (1) CA2866872A1 (zh)
EA (1) EA028414B1 (zh)
ES (1) ES2677874T3 (zh)
HK (1) HK1201750A1 (zh)
IL (1) IL234602B (zh)
MX (1) MX360878B (zh)
MY (1) MY174022A (zh)
NI (1) NI201400111A (zh)
NZ (1) NZ628416A (zh)
PH (1) PH12014502029A1 (zh)
SG (1) SG11201405707XA (zh)
TW (1) TWI583385B (zh)
UA (1) UA114315C2 (zh)
WO (1) WO2013138557A1 (zh)
ZA (1) ZA201406706B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210071101A (ko) * 2012-03-15 2021-06-15 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자를 사용하는 암의 치료
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201441227A (zh) 2013-01-16 2014-11-01 Signal Pharm Llc 經取代吡咯并嘧啶化合物、其組合物及其治療方法
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
WO2014172424A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
WO2008051494A1 (en) 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
BR112012009751A2 (pt) 2009-10-26 2020-09-24 Signal Pharmaceuticals, Llc métodos de síntese e purificação de heteroarila
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
KR20210071101A (ko) * 2012-03-15 2021-06-15 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자를 사용하는 암의 치료

Also Published As

Publication number Publication date
EA201491699A1 (ru) 2015-02-27
JP2021102637A (ja) 2021-07-15
KR20200070416A (ko) 2020-06-17
CA2866872A1 (en) 2013-09-19
EP2825170B1 (en) 2018-05-09
MX360878B (es) 2018-11-21
TW201343168A (zh) 2013-11-01
UA114315C2 (uk) 2017-05-25
US20130245026A1 (en) 2013-09-19
NI201400111A (es) 2015-01-15
IL234602A0 (en) 2014-11-30
WO2013138557A1 (en) 2013-09-19
EA028414B1 (ru) 2017-11-30
NZ628416A (en) 2016-04-29
ZA201406706B (en) 2016-05-25
KR102122617B1 (ko) 2020-06-12
CN104519885A (zh) 2015-04-15
SG11201405707XA (en) 2014-10-30
ES2677874T3 (es) 2018-08-07
AU2013203153B2 (en) 2015-09-03
TWI583385B (zh) 2017-05-21
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
JP2015510891A (ja) 2015-04-13
PH12014502029B1 (en) 2014-11-24
IL234602B (en) 2020-05-31
KR20140138927A (ko) 2014-12-04
PH12014502029A1 (en) 2014-11-24
JP2019108368A (ja) 2019-07-04
AU2013203153A1 (en) 2013-10-03
BR112014022703A2 (pt) 2021-05-04
MY174022A (en) 2020-03-04
EP2825170A1 (en) 2015-01-21
KR20210071101A (ko) 2021-06-15

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
HK1202247A1 (zh) 激酶抑制劑治療癌症
HK1201750A1 (zh) 使用 激酶抑制劑的癌症治療
HK1220640A1 (zh) 用谷氨醯胺酶的雜環抑制劑治療癌症
HK1201753A1 (zh) 使用 激酶抑制劑的癌症治療
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (zh) 癌症治療
HK1205500A1 (zh) 用於癌症治療的激酶抑制劑
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
GB201217890D0 (en) Treatment of cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
GB201208296D0 (en) Treatment of cancer